Tufts University School of Medicine, Boston, Massachusetts.
Am Fam Physician. 2023 May;107(5):545-546.
Cabotegravir (Apretude) is an extended-release injectable HIV type 1 (HIV-1) antiretroviral integrase strand transfer inhibitor. Cabotegravir is labeled for use in adults and adolescents weighing at least 35 kg (77 lb) who are HIV-negative but at risk of HIV-1. It is used as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection, the most common form of HIV.1.
卡博特韦（Apretude）是一种长效注射型 HIV 型 1（HIV-1）抗逆转录病毒整合酶链转移抑制剂。卡博特韦被批准用于体重至少为 35 公斤（77 磅）的 HIV 阴性但有 HIV-1 感染风险的成年人和青少年。它被用于暴露前预防（PrEP）以降低性传播 HIV-1 感染的风险，这是 HIV 最常见的形式。1。
